HC Wainwright upgraded Sutro Biopharma (STRO) from Neutral to Buy on March 24, 2026; the analyst's price forecast implies a 55.41% upside. The upgrade is a materially positive analyst signal that could trigger short-term re-rating or increased buying interest in the stock. Monitor share-price reaction and trading volume for confirmation and review the analyst note for the drivers behind the higher target.
HC Wainwright upgraded Sutro Biopharma (STRO) from Neutral to Buy on March 24, 2026; the analyst's price forecast implies a 55.41% upside. The upgrade is a materially positive analyst signal that could trigger short-term re-rating or increased buying interest in the stock. Monitor share-price reaction and trading volume for confirmation and review the analyst note for the drivers behind the higher target.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
